SHARPE
Reported results
- Third quarter 2026 net product revenues were $21.0 million, compared to $15.8 million for the third quarter of 2025.
- GAAP net loss for the third quarter of 2026 was $25.3 million, or $0.16 per basic and diluted share, compared to a GAAP net loss of $41.0 million, or $0.30 per basic and diluted share, for the third quarter of 2025.
- Non-GAAP adjusted net loss for the third quarter of 2026 was $8.8 million, or $0.06 per basic and diluted share, compared to a non-GAAP adjusted net loss of $25.5 million, or $0.19 per basic and diluted share, for the third quarter of 2025.
- GAAP total operating expenses were $36.1 million for the third quarter of 2026, a reduction of 24% compared to $47.4 million for the third quarter of 2025.
- Non-GAAP total adjusted operating expenses were $32.1 million for the third quarter of 2026, a reduction of 29% compared to $45.0 million for the third quarter of 2025.
- Cash and cash equivalents were $189.2 million as of September 30, 2026, compared to $261.3 million as of December 31, 2025.
Guidance
- The Company has an expected cash runway into 2029.
Notes
In October 2026, the Company completed a strategic financial restructuring that included an $86.6 million private investment in public equity (PIPE) financing, amendments to its HealthCare Royalty financing agreement to eliminate a $150 million change-of-control payment, and amendments to its senior secured loan agreement reducing outstanding principal by $68.5 million to $50 million.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.